India issues draft bioequivalence request format for drugs aimed for export

SINGAPORE--A uniform format by India's Central Drugs Standard Control Organization (CDSCO) to file requests for bioequivalence studies in India on drugs manufactured for export put into a draft for comment.

The draft covers study requests for: New molecules approved in other countries but not India; drugs approved in India within one year; drugs approved in India in a period of one to four years; drugs in modified release form irrespective of their approval status; and so-called old drugs approved in India for more than four years. The deadline for comments is Jan. 25, 2015.

- view the draft (PDF)

Suggested Articles

After early threats, the FDA finished reviewing the company's response to a citation for data manipulation and decided not to take any further action.

China is quickly getting back up to speed with API production but reports freight bottlenecks are slowing deliveries.

Mylan and Pfizer have already postponed the close of their generic merger amid COVID-19 concerns. Now the pair is hoping to speed up EU review.